DRKS00004531招募中2 期
A Phase 2, Open Label, Ascending Dose Study of ACE-536 for the Treatment of Anemia in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) - A536-03
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomized controlled study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •1. Men or women = 18 years of age.
- •2. Documented diagnosis of idiopathic/de novo MDS or non-proliferative chronic myelomonocytic leukemia (CMML) according to WHO criteria16 (white blood count [WBC] < 13,000/µL) that meets International Prognostic Scoring System (IPSS) classification (Appendix 2) of low or intermediate-1 risk disease as determined by microscopic and standard cytogenetic analyses of the bone marrow and peripheral complete blood count (CBC) obtained during screening.
- •3. Anemia defined as:
- •- Mean hemoglobin concentration < 10.0 g/dL of 2 measurements (one performed within one day prior to Cycle 1 Day 1 and the other performed 7-28 days prior to Cycle 1 Day 1, not influenced by RBC transfusion within 7 days of measurement) for non-transfusion dependent patients (defined as having received ? 4 units of RBCs within 8 weeks prior to Cycle 1 Day 1), OR
- •- Transfusion dependent, defined as having received = 4 units of RBCs within 8 weeks prior to Cycle 1 Day 1.
- •4. Serum erythropoietin level > 500 U/L, OR, if = 500 U/L, patient is non-responsive, refractory, or intolerant to erythropoiesis-stimulating agents (ESAs), or ESAs are contraindicated or unavailable.
- •5. No alternative treatment options, per national MDS guidelines, are available and/or appropriate for the patient, at the discretion of the investigator.
- •6. ECOG performance status of 0, 1, or 2 (if related to anemia).
- •7. Adequate renal (creatinine = 2 x upper limit of normal [ULN]) and hepatic (total bilirubin < 2 x ULN and AST and ALT < 3 x ULN) function.
- •8. Adequate transferrin saturation (= 15%), ferritin (= 50 µg/L), folate (= 4.5 nmol/L [= 2.0 µg/L]) and vitamin B12 (= 148 pmol/L [= 200 pg/mL]) during screening (supplementation and retest during screening is acceptable).
- •9. Females of child bearing potential (defined as sexually mature women who have not undergone hysterectomy or bilateral oophorectomy, or are not naturally postmenopausal = 24 consecutive months) must have negative urine or blood pregnancy test prior to enrollment and use adequate birth control methods (abstinence, oral contraceptives, barrier method with spermicide, or surgical sterilization) during study participation. Males must agree to use a latex condom during any sexual contact with females of child-bearing potential while participating in the study and for 12 weeks following the last dose of ACE 536, even if he has undergone a successful vasectomy. Patients must be counseled concerning measures to be used to prevent pregnancy and potential toxicities prior to the first dose of ACE-536.
- •10. Patients are able to adhere to the study visit schedule, understand and comply with all protocol requirements.
- •11. Patient understands and is able to provide written informed consent.
排除标准
- •1. Prior treatment with azacitidine or decitabine.
- •2. Treatment within 28 days prior to Cycle 1 Day 1 with:
- •- Erythropoiesis stimulating agent (ESA),
- •- Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF),
- •- Lenalidomide.
- •3. Iron chelation therapy if initiated within 56 days prior to Cycle 1 Day 1.
- •4. Treatment with another investigational drug or device, or approved therapy for investigational use = 28 days prior to Cycle 1 Day 1, or if the half-life of the previous product is known, within 5 times the half-life prior to Cycle 1 Day 1, whichever is longer.
- •5. Major surgery within 28 days prior to Cycle 1 Day 1. Patients must have completely recovered from any previous surgery prior to Cycle 1 Day 1.
- •6. Platelet count < 30 x 109/L.
- •7. Any active infection requiring parenteral antibiotic therapy within 28 days prior to Cycle 1 Day 1 or oral antibiotics within 14 days of Cycle 1 Day 1.
- •8. History of stroke, deep venous thrombosis (DVT) or arterial embolism within 6 months prior to Cycle 1 Day 1.
- •9. Known positive for human immunodeficiency virus (HIV), active infectious hepatitis B (HBV) or active infectious hepatitis C (HCV).
- •10. Any malignancy other than MDS which has not been in remission and/or has required systemic therapy including radiation, chemotherapy, hormonal therapy or surgery, within the last year prior to Cycle 1 Day 1.
- •11. Uncontrolled hypertension, defined as systolic blood pressure (BP) = 150 mm Hg or diastolic BP = 100 mm Hg.
- •12. Pregnant or lactating females.
- •13. History of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational drug.
- •14. Any other condition not specifically noted above which, in the judgment of the investigator, would preclude the patient from participating in the study.
- •15. Transfusion event within 7 days prior to Cycle 1 Day 1.
- •16. Prior treatment with sotatercept (ACE-011) or ACE-536.
研究者
相似试验
进行中（未招募）
1 期
A Phase 2 study for the treatment of anemia in patients with myelodysplastic syndrome of low and intermediate risk groups with increasing doses of ACE-536EUCTR2012-002523-14-DEAcceleron Pharma Inc.153
进行中（未招募）
不适用
A clinical study of a new drug for the treatment of thalassemiaß-thalassemia intermediaMedDRA version: 15.1Level: LLTClassification code 10062923Term: Thalassemia intermediaSystem Organ Class: 100000004850MedDRA version: 15.1Level: LLTClassification code 10054660Term: Thalassemia betaSystem Organ Class: 100000004850EUCTR2012-002499-15-ITACCELERON PHARMA INC
进行中（未招募）
1 期
A Phase 2 study with increasing doses of a new medication called ACE-536 in patients suffering from ß-Thalassemia IntermediaEUCTR2012-002499-15-GRAcceleron Pharma, Inc.50
进行中（未招募）
1 期
Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid LeukemiaRelapsed or Refractory Acute Myeloid LeukemiaMedDRA version: 17.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864EUCTR2014-002217-31-ITAstellas Pharma Global Development, Inc.265
进行中（未招募）
1 期
Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid LeukemiaRelapsed or Refractory Acute Myeloid LeukemiaMedDRA version: 18.1 Level: LLT Classification code 10000886 Term: Acute myeloid leukemia System Organ Class: 100000004864EUCTR2014-002217-31-DEAstellas Pharma Global Development, Inc.265